Ann Marie Návar

11.2k total citations · 9 hit papers
167 papers, 5.4k citations indexed

About

Ann Marie Návar is a scholar working on Surgery, Economics and Econometrics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Ann Marie Návar has authored 167 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Surgery, 57 papers in Economics and Econometrics and 54 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Ann Marie Návar's work include Lipoproteins and Cardiovascular Health (74 papers), Health Systems, Economic Evaluations, Quality of Life (48 papers) and Pharmaceutical Economics and Policy (27 papers). Ann Marie Návar is often cited by papers focused on Lipoproteins and Cardiovascular Health (74 papers), Health Systems, Economic Evaluations, Quality of Life (48 papers) and Pharmaceutical Economics and Policy (27 papers). Ann Marie Návar collaborates with scholars based in United States, United Kingdom and Canada. Ann Marie Návar's co-authors include Michael Pencina, Benjamin A. Goldstein, Eric D. Peterson, John P. A. Ioannidis, Rickey E. Carter, Salim S. Virani, Allan D. Sniderman, Tracy Y. Wang, Jennifer G. Robinson and Michael G. Nanna and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Ann Marie Návar

150 papers receiving 5.3k citations

Hit Papers

Opportunities and challenges in developing risk predictio... 2016 2026 2019 2022 2016 2016 2019 2019 2023 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review
    2016 548 citations Benjamin A. Goldstein, Ann Marie Návar et al. Journal of the American Medical Informatics Association profile →
  2. Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges
    2016 363 citations Benjamin A. Goldstein, Ann Marie Návar et al. profile →
  3. Apolipoprotein B Particles and Cardiovascular Disease
    2019 335 citations Ann Marie Návar, Michael Pencina et al. JAMA Cardiology profile →
  4. Sex Differences in the Use of Statins in Community Practice
    2019 197 citations Michael G. Nanna, Eric D. Peterson et al. Circulation Cardiovascular Quality and Outcomes profile →
  5. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)
    2023 124 citations Steven E. Nissen, Kathy Wolski et al. JAMA profile →
  6. Managing Atherosclerotic Cardiovascular Risk in Young Adults
    2022 118 citations Ann Marie Návar, Michael Pencina et al. Journal of the American College of Cardiology profile →
  7. Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
    2024 49 citations Steven E. Nissen, Qiuqing Wang et al. JAMA profile →
  8. Oral Muvalaplin for Lowering of Lipoprotein(a)
    2024 48 citations Stephen J. Nicholls, Ann Marie Návar et al. JAMA profile →
  9. Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
    2025 27 citations Steven E. Nissen, Qiuqing Wang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ann Marie Návar United States 37 1.8k 1.4k 977 920 857 167 5.4k
Fátima Rodríguez United States 36 1.0k 0.6× 2.1k 1.5× 733 0.8× 506 0.6× 483 0.6× 245 5.5k
Rohan Khera United States 45 1.2k 0.7× 2.7k 1.9× 814 0.8× 1.1k 1.2× 644 0.8× 263 7.0k
Sean Hennessy United States 50 1.1k 0.6× 1.2k 0.9× 732 0.7× 1.0k 1.1× 659 0.8× 268 8.7k
Spiros Denaxas United Kingdom 40 811 0.4× 2.7k 1.9× 491 0.5× 1.3k 1.4× 1.1k 1.3× 186 7.7k
Mark D. Huffman United States 42 1.8k 1.0× 3.3k 2.4× 1.2k 1.2× 693 0.8× 931 1.1× 250 7.8k
Rohini Mathur United Kingdom 33 555 0.3× 872 0.6× 477 0.5× 1.4k 1.5× 1.1k 1.3× 120 5.9k
Olaf H. Klungel Netherlands 48 1.3k 0.7× 2.3k 1.6× 2.0k 2.0× 855 0.9× 1.2k 1.4× 314 8.8k
Dhruv S. Kazi United States 34 1.2k 0.6× 1.5k 1.1× 1.1k 1.1× 582 0.6× 431 0.5× 144 4.7k
Ian Douglas United Kingdom 37 952 0.5× 963 0.7× 436 0.4× 1.0k 1.1× 698 0.8× 155 7.0k
Juan P. Casas United Kingdom 46 1.2k 0.6× 2.3k 1.6× 394 0.4× 1.2k 1.4× 977 1.1× 127 8.5k

Countries citing papers authored by Ann Marie Návar

Since Specialization
Citations

This map shows the geographic impact of Ann Marie Návar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Marie Návar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Marie Návar more than expected).

Fields of papers citing papers by Ann Marie Návar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Marie Návar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Marie Návar. The network helps show where Ann Marie Návar may publish in the future.

Co-authorship network of co-authors of Ann Marie Návar

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Marie Návar. A scholar is included among the top collaborators of Ann Marie Návar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Marie Návar. Ann Marie Návar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Perkovic, Vlado, Katherine R. Tuttle, Naveed Sattar, et al.. (2025). WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE. Kidney International Reports. 10(2). S767–S768. 6 indexed citations
2.
Grubb, Christopher S., Catherine Chen, Corey D. Kershaw, et al.. (2025). Management Patterns and Outcomes of Invasive Mechanical Ventilation in Patients With Cardiogenic Shock. JACC Advances. 4(10). 101916–101916.
3.
Dupre, Matthew E., Hanzhang Xu, Scott M. Lynch, et al.. (2025). Racial and ethnic disparities in longitudinal trajectories of cardiovascular risk factors in U.S. middle-aged and older adults. PLoS ONE. 20(2). e0318419–e0318419. 1 indexed citations
4.
Ray, Kausik K., Mads Faurby, Jimmi Mathisen, et al.. (2025). Factors associated with elevated high-sensitivity C-reactive protein levels in individuals with atherosclerotic cardiovascular disease in the USA and the UK. European Journal of Preventive Cardiology. 33(5). 643–652. 1 indexed citations
5.
Návar, Ann Marie, Daniel X. Yang, Dong Soo Lee, et al.. (2025). ChatGPT augmented clinical trial screening. SHILAP Revista de lepidopterología. 1(1). 15005–15005.
6.
Knowlton, Kirk U., Ann Marie Návar, Jeffrey Anderson, et al.. (2025). LDL-C management with inclisiran plus usual care vs usual care alone in participants with recent acute coronary syndrome: VICTORION-INCEPTION. Journal of clinical lipidology. 19(3). e109–e110. 2 indexed citations
7.
Ray, Kausik K., Michael Szarek, Ann Marie Návar, et al.. (2025). Effect of Obicetrapib on New Onset Diabetes In Patients with Elevated LDL-C Receiving Maximally Tolerated Statin Therapy: Pooled Analyses of the Broadway and Brooklyn Trials. Journal of clinical lipidology. 19(3). e116–e117. 1 indexed citations
8.
Liu, Jialiang, Donghan M. Yang, Yang Xie, et al.. (2024). Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus. JAMA Dermatology. 161(2). 175–175. 1 indexed citations
9.
Nissen, Steven E., Qiuqing Wang, Stephen J. Nicholls, et al.. (2024). Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a). JAMA. 332(23). 1992–1992. 49 indexed citations breakdown →
10.
Joshi, Parag H., et al.. (2024). Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. Circulation. 150(1). 62–79. 12 indexed citations
11.
Rao, Anjali, Ann Marie Návar, Anand Rohatgi, et al.. (2024). Measurement and Application of Incidentally Detected Coronary Calcium. Journal of the American College of Cardiology. 83(16). 1557–1567. 5 indexed citations
12.
Ayers, Colby, Parag H. Joshi, Arzu Canan, et al.. (2023). Accuracy of incidental visual coronary artery calcium assessment compared with dedicated coronary artery calcium scoring. Journal of cardiovascular computed tomography. 17(6). 453–458. 3 indexed citations
13.
Peterson, Eric D., et al.. (2023). Lipid-lowering therapy and LDL-C control for primary prevention in persons with diabetes across 90 health systems in the United States. SHILAP Revista de lepidopterología. 16. 100604–100604. 1 indexed citations
14.
Jacobs, Joshua A., Alexander R. Zheutlin, Catherine G. Derington, et al.. (2023). Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US. JAMA Cardiology. 8(5). 443–443. 36 indexed citations
15.
Návar, Ann Marie, et al.. (2021). The impact of race and ethnicity on outcomes in 19,584 adults hospitalized with COVID-19. PLoS ONE. 16(7). e0254809–e0254809. 21 indexed citations
16.
Orroth, Kate K., Alexander Breskin, Andrew S. Park, et al.. (2021). Use of negative control outcomes to assess the comparability of patients initiating lipid‐lowering therapies. Pharmacoepidemiology and Drug Safety. 31(4). 383–392. 9 indexed citations
17.
Dupre, Matthew E., Heather R. Farmer, Hanzhang Xu, et al.. (2021). The Cumulative Impact of Chronic Stressors on Risks of Myocardial Infarction in US Older Adults. Psychosomatic Medicine. 83(9). 987–994. 1 indexed citations
18.
19.
Sumarsono, Andrew, Hussain S. Lalani, Matthew W. Segar, et al.. (2020). Association of Medicaid Expansion With Rates of Utilization of Cardiovascular Therapies Among Medicaid Beneficiaries Between 2011 and 2018. Circulation Cardiovascular Quality and Outcomes. 14(1). e007492–e007492. 16 indexed citations
20.
Goldstein, Benjamin A., Ann Marie Návar, Michael Pencina, & John P. A. Ioannidis. (2016). Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. Journal of the American Medical Informatics Association. 24(1). 198–208. 548 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fátima Rodríguez Breakdown of academic impact, for papers by Rohan Khera Breakdown of academic impact, for papers by Sean Hennessy Breakdown of academic impact, for papers by Spiros Denaxas Breakdown of academic impact, for papers by Mark D. Huffman Breakdown of academic impact, for papers by Rohini Mathur Breakdown of academic impact, for papers by Olaf H. Klungel Breakdown of academic impact, for papers by Dhruv S. Kazi Breakdown of academic impact, for papers by Ian Douglas Breakdown of academic impact, for papers by Juan P. Casas
Rankless by CCL
2026